000097402 001__ 97402
000097402 005__ 20210902121839.0
000097402 0247_ $$2doi$$a10.1088/1748-605X/aba445
000097402 0248_ $$2sideral$$a121787
000097402 037__ $$aART-2020-121787
000097402 041__ $$aeng
000097402 100__ $$aPrieto, E.
000097402 245__ $$aDexamethasone delivery to the ocular posterior segment by sustained-release Laponite formulation
000097402 260__ $$c2020
000097402 5060_ $$aAccess copy available to the general public$$fUnrestricted
000097402 5203_ $$aThis paper presents a novel nanoformulation for sustained-release delivery of dexamethasone (DEX) to the ocular posterior segment using a Laponite (LAP) carrier - DEX/LAP 1:10 w w-1 formulation; 10 mg ml-1. In vivo ocular feasibility and pharmacokinetics after intravitreal (IV) and suprachoroidal (SC) administration in rabbit eyes are compared against IV administration of a DEX solution (1 mg ml-1). Thirty rabbit eyes were injected with the DEX/LAP formulation (15 suprachoroid/15 intravitreous). Ophthalmological signs were monitored at day 1 and at weeks 1-4-12-24 post-administration. Three eyes per sample time point were used to quantify DEX concentration using high-performance liquid chromatography-mass spectrometry. The ocular tissues'' pharmacokinetic parameters (lens, vitreous humour, choroid-retina unit and sclera) were studied. DEX/LAP was well tolerated under both administration methods. Peak intraocular DEX levels from the DEX/LAP were detected in the vitreous humour after both deliveries soon after administration. The vitreous area under the curve was significantly greater after both DEX/LAP deliveries (IV: 205 968.47; SC: 11 442.22 ng g-1 d-1) than after IV administration of the DEX solution (317.17 ng g-1 d-1). Intravitreal DEX/LAP delivery extended higher vitreous DEX levels up to week 24 (466.32 311.15 ng g-1). With SC delivery, DEX levels were detectable in the choroid-retina unit (12.04 20.85 ng g-1) and sclera (25.46 44.09 ng g-1) up to week 24. This study demonstrated the intraocular feasibility of both SC and IV administration of the DEX/LAP formulation. The LAP increased the intraocular retention time of DEX when compared with conventional solutions. DEX/LAP could be considered a biocompatible and useful sustained-release formulation for treating posterior-pole eye diseases.
000097402 536__ $$9info:eu-repo/grantAgreement/ES/DGA/E37-17R$$9info:eu-repo/grantAgreement/ES/DGA-FEDER/Construyendo Europa desde Aragón$$9info:eu-repo/grantAgreement/ES/ISCIII/M17-00213$$9info:eu-repo/grantAgreement/ES/ISCIII/PI12-02285$$9info:eu-repo/grantAgreement/ES/ISCIII/PI17-01726$$9info:eu-repo/grantAgreement/ES/ISCIII/PI17-01946$$9info:eu-repo/grantAgreement/ES/MINECO-AEI-FEDER/MAT2017-83858-C2-2
000097402 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000097402 590__ $$a3.715$$b2020
000097402 591__ $$aENGINEERING, BIOMEDICAL$$b39 / 90 = 0.433$$c2020$$dQ2$$eT2
000097402 591__ $$aMATERIALS SCIENCE, BIOMATERIALS$$b24 / 40 = 0.6$$c2020$$dQ3$$eT2
000097402 592__ $$a0.743$$b2020
000097402 593__ $$aBioengineering$$c2020$$dQ1
000097402 593__ $$aBiomaterials$$c2020$$dQ1
000097402 593__ $$aMechanics of Materials$$c2020$$dQ1
000097402 593__ $$aBusiness and International Management$$c2020$$dQ1
000097402 593__ $$aChemistry (miscellaneous)$$c2020$$dQ1
000097402 593__ $$aBiomedical Engineering$$c2020$$dQ1
000097402 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000097402 700__ $$0(orcid)0000-0002-7914-4685$$aCardiel, M.J.$$uUniversidad de Zaragoza
000097402 700__ $$0(orcid)0000-0002-4921-4734$$aVispe, E.
000097402 700__ $$aIdoipe, M.
000097402 700__ $$0(orcid)0000-0001-6258-2489$$aGarcia-Martin, E.$$uUniversidad de Zaragoza
000097402 700__ $$0(orcid)0000-0002-0136-5138$$aFraile, J.M.$$uUniversidad de Zaragoza
000097402 700__ $$0(orcid)0000-0002-1402-3129$$aPolo, V.$$uUniversidad de Zaragoza
000097402 700__ $$0(orcid)0000-0003-1570-4257$$aMayoral, J.A.$$uUniversidad de Zaragoza
000097402 700__ $$0(orcid)0000-0003-2389-8282$$aPablo, L.E.$$uUniversidad de Zaragoza
000097402 700__ $$aRodrigo, M.J.
000097402 7102_ $$12013$$2765$$aUniversidad de Zaragoza$$bDpto. Química Orgánica$$cÁrea Química Orgánica
000097402 7102_ $$11013$$2646$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Oftalmología
000097402 7102_ $$11013$$2020$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Anatomía Patológica
000097402 773__ $$g15, 6 (2020), 065021 [14 pp]$$pBiomedical Materials$$tBiomedical Materials$$x1748-6041
000097402 8564_ $$s503394$$uhttps://zaguan.unizar.es/record/97402/files/texto_completo.pdf$$yVersión publicada
000097402 8564_ $$s92307$$uhttps://zaguan.unizar.es/record/97402/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000097402 909CO $$ooai:zaguan.unizar.es:97402$$particulos$$pdriver
000097402 951__ $$a2021-09-02-10:22:31
000097402 980__ $$aARTICLE